You are here

IGF::OT::IGF OTHER FUNCTIONS - RandD BIOMEDICAL (BASIC RESEARCH)

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CO120083
Agency Tracking Number: N43CO120083
Amount: $187,222.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
INTEZYNE TECHNOLOGIES, INC. 3720 SPECTRUM BLVD, STE 104
TAMPA, FL 33612-
United States
DUNS: 002002948
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KEVIN SILL
 (813) 910-2120
 KEVIN.SILL@INTEZYNE.COM
Business Contact
 KEVIN SILL
Phone: (813) 910-2120
Email: KEVIN.SILL@INTEZYNE.COM
Research Institution
 Stub
Abstract

This project aims to develop a stabilized epothilone B (Epo B)-loaded micelle for the intravenous delivery of Epo B to solid tumors. The data should demonstrate that Epo B is encapsulated within the micelle with weight-loadings in the range of 1-5% wt/wt Epo B. Crosslinking chemistries will be applied to Epo B-loaded micelles to generate a crosslinked, stabilized, Epo B micelle. It is anticipated that the particle size of micelles will be between 30-100nm. Based on previous studies with iron-crosslinked micelles, pH-dependent release of Epo B is expected in vitro. Crosslinked Epo B micelles are also expected to be more stable in serum than un-crosslinked micelles, in vitro. Administration of crosslinked micelles to cancer cells in vitro should exhibit similar if not identical cytotoxicity as free Epo B. In vivo characterization should result in: (a) determination of the maximum tolerated dose (MTD) of the Epo B micelle in nude mice; (b) the pharmacokinetics of the Epo B micelle compared to free Epo B in nudemice; and (c) the antitumor efficacy of the micelle in two xenograft models. It is anticipated that the Epo B micelle will outperform free drug in terms of having a higher MTD, superior pharmacokinetics, and improved antitumor efficacy compared to free EpoB.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government